[Antibacterial activity in vitro and clinical use of sulperazon].
In order to approach antibacterial activity in vitro and the efficacy of Sulperazon (SPZ) (sulbactam/cefoperazone), the sensitivity tests of 1,372 strains from clinical isolated bacteria to 17 antibiotics including SPZ were determined. The Gram negative bacteria occupied 1,035 strains (75.4) and Gram positive 337 strains (24.6%). 50 episodes of infections of major respiratory system in 43 patients were treated by SPZ. 58% of bacterial infections occurred in hematologic malignant diseases and solid tumors patients. 24% of 50 episodes were in neutropenia status. The positive rate of bac-terial cluteres was 56% in the series. 1.0-2.0 g SPZ was administered twice a day for 5-18 days, 56% of them was more than seven days (28/50 episodes). The results of susceptibility tests showed that sensitive rates were most high and the nesistant rates of SPZ were lower than these of to common Gram negative and Gram positive bacteria in third-generation cephalosporins. The efficacy rate of SPZ in clinical use was 84% (42/50 episodes), bacterial clearance rate was 89% (25/28 episodes). Three cases (6%) had temporary elevation and other adverse reactions of SPZ were not seen.